Recent evidence suggests that GLP-1 receptor agonists may play a role beyond metabolic control. A new randomized clinical trial published in JAMA Psychiatry explores the potential of Semaglutide for Motivation in MDD. This secondary analysis evaluated whether activating these receptors could address reward-related dysfunction. Furthermore, it specifically examined anhedonia, a core feature of depression that often remains resistant to standard antidepressants.

The 16-week, double-blind, placebo-controlled trial involved 72 participants diagnosed with Major Depressive Disorder (MDD). Specifically, all participants had a body mass index (BMI) of 25 or higher. Researchers randomized them to receive either 14 mg of oral semaglutide or a placebo. Therefore, they could directly compare the effects of the intervention against a control group. The study primarily focused on performance in the Effort-Expenditure for Rewards Task (EEfRT). This task assesses how much effort an individual willingly expends for varying levels of monetary reward.

Significantly, participants treated with semaglutide exhibited an increased willingness to exert physical effort for higher expected reward values. Computational modeling revealed that the medication effectively reduced "effort discounting." This indicates that patients perceived the cost of effort as lower relative to the potential reward. Additionally, while semaglutide improved sensitivity to effort, it did not significantly alter sensitivity to the probability of winning. Consequently, the drug appears to target the energy-related components of motivation specifically.

Clinical Impact of Semaglutide for Motivation in MDD

These findings offer a novel perspective on managing motivational deficits in psychiatric care. Standard treatments often fail to address the lack of drive seen in many depressed patients. Moreover, metabolic mechanisms appear to play a critical role in effort-based motivation. Therefore, GLP-1 receptor agonists might serve as valuable adjunctive therapies in the future. However, clinicians must remember that this was a secondary analysis. Larger, primary studies are necessary to confirm these antidepressive effects and ensure long-term safety in psychiatric populations.

How does semaglutide affect the brain in depression?

Semaglutide activates GLP-1 receptors in brain regions responsible for reward and dopamine signaling. By modulating these pathways, it may reduce the subjective cost of effort, making it easier for patients to engage in goal-directed behaviors.

Is semaglutide currently recommended for MDD?

No, semaglutide is currently only approved for type 2 diabetes and weight management. Although this trial shows positive results for motivation, it is not yet a standard treatment for Major Depressive Disorder.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

Gill H et al. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Apr 29. doi: 10.1001/jamapsychiatry.2026.0594. PMID: 42054055.

Mansur RB et al. Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Med. 2026 Jan 9;7(1):100916. doi: 10.1016/j.medj.2025.100916.

Science Media Centre. Expert reaction to RCT which looks at semaglutide and motivation in depression. 2026 Apr 29.